794Bisphosphonate use and risk of ovarian cancer, a nested case-control study using national health data

Abstract Background Epithelial ovarian cancer (EOC) is the eighth most common cancer in women, has a five-year survival of ∼45%, and very few established modifiable risk factors. Some evidence suggests that bisphosphonates could have chemopreventive benefits, but few epidemiological studies have investigated the association between bisphosphonate use and incidence of EOC. Methods We conducted a nested case-control study using linked administrative data. We identified 9,367 women over 50 years diagnosed with EOC (cases) from 2004 to 2013, and for each case identified five controls from the Australian Medicare Enrolment database matched by age, state, area of residence, and area-level socioeconomic disadvantage. We assessed the associations between bisphosphonate use using dispensed prescription data (ever use, duration and dose) and EOC (overall, by histotype), adjusting for comorbidities and MHT use. We conducted sensitivity analyses in women with complete ascertainment of dispensing claims and for residents of one Australian state that had linked with data linked to hospital procedures, including oophorectomy. Results Our analyses show an inverse association between bisphosphonate use and risk of EOC overall (OR = 0.81, 95%CI:0.75-0.88), and for endometrioid (OR = 0.51, 95%CI:0.33-0.79) and serous (OR = 0.84, 95%CI:0.75-0.93) histotypes. There was some evidence that higher dose and duration were associated with a greater reduction in risk. Results from sensitivity analyses were not appreciably different. Conclusions Bisphosphonate use was associated with lower risk of EOC, suggesting bisphosphonates may reduce risk of ovarian cancer development. Key messages Bisphosphonates may protect against development of serous and endometrioid ovarian cancers.

Download Full-text

Plasma Adiponectin and the Risk of Hypertension in White and Black Postmenopausal Women

Clinical Chemistry ◽

10.1373/clinchem.2012.191080 ◽

2012 ◽

Vol 58 (10) ◽

pp. 1438-1445 ◽

Cited By ~ 8

Author(s):

Lu Wang ◽

JoAnn E Manson ◽

J Michael Gaziano ◽

Simin Liu ◽

Barbara Cochrane ◽

...

Keyword(s):

Black Women ◽

Postmenopausal Women ◽

White Women ◽

Case Control Study ◽

Plasma Concentrations ◽

Case Control ◽

Inverse Association ◽

Plasma Adiponectin ◽

Nested Case Control ◽

Control Study

Abstract BACKGROUND Adiponectin may have a protective role in the development of obesity-related metabolic and vascular disorders, including hypertension. We conducted a prospective, nested case control study to investigate the relation between baseline plasma adiponectin, measures of adiposity, and subsequent risk of hypertension. METHODS We selected 400 white and 400 black postmenopausal women, age <70 years, who developed incident hypertension during 5.9-year follow-up and an equal number of age- and race-matched controls in the Women's Health Initiative Observational Study. We measured plasma concentrations of total adiponectin in their baseline blood samples. RESULTS In crude matched models, plasma adiponectin was inversely associated with risk of hypertension among both white and black women. The association appeared to be nonlinear in white women but dose related in black women. Adjustment for lifestyle factors, measures of obesity, and obesity-related clinical factors attenuated these associations. The multivariable relative risk (95% CI) of hypertension across increasing quartiles of plasma adiponectin were 1.00, 0.98 (0.66–1.46), 0.63 (0.41–0.97), and 0.92 (0.60–1.42) in white women (Ptrend: 0.38) and 1.00, 0.96 (0.64–1.46), 0.83 (0.53–1.29), and 0.58 (0.36–0.94) in black women (Ptrend: 0.02). Further adjustment for inflammatory markers and endothelial markers eliminated the association in white, but not black, women. CONCLUSIONS In this prospective, nested case control study, we found an inverse association between plasma adiponectin and risk of hypertension in white and black postmenopausal women. The reduced risk of hypertension was limited to only intermediate concentrations of adiponectin in white women whereas it was graded across quartiles of adiponectin in black women.

Download Full-text

The association between proton pump inhibitors (PPI) use for gastro-esophageal reflux disease (GERD) and lung cancer (LC): A nested case-control study.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.1562 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. 1562-1562

Author(s):

Hadas Dresler ◽

Daniel Keizman ◽

Ronac Mamtani ◽

Maya Gottfried ◽

Natalie Maimon ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Risk ◽

Cancer Diagnosis ◽

Case Control Study ◽

Lung Cancer Risk ◽

Case Control ◽

Sensitivity Analyses ◽

Diagnostic Code ◽

Nested Case Control ◽

Control Study

1562 Background: Data suggests that GERD with recurrent reflux and microaspiration of stomach contents, may be associated with lung injury, inflammation, activation of proliferative signals, and eventually DNA damage and malignant transformation. Recently, a large population based cohort study found that GERD may increase the risk of lung cancer in Asians. In the present nested case control study, we aimed to evaluate the association between PPI use as a surrogate for GERD and lung cancer in a large western population. Methods: We conducted a matched case-control study within a population-representative database from the United Kingdom. Study cases were defined as individuals with any diagnostic code of lung cancer. For every case, four eligible controls were matched on age, gender, practice site, time and duration of follow-up. Exposure of interest was PPI use prior to cancer diagnosis. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for lung cancer were estimated using conditional logistic regression. Adjustment was performed for smoking. Results: The study population included 19143 lung cancer cases and 74473 matched controls. PPI use was associated with a significantly increased lung cancer risk (adjusted OR 1.70, 95%CI 1.64-1.77, p < 0.001). In a sensitivity analyses we observed similar associations when PPI use was initiated more than one year prior to cancer diagnosis (adjusted OR 1.18, 95%CI 1.13-1.23, p < 0.001) and more than two years prior to cancer diagnosis (adjusted OR 1.15, 95%CI 1.10-1.20, p < 0.001) Conclusions: ChronicPPI use, as a surrogate for symptomatic GERD, may be associated with a higher lung cancer risk.

Download Full-text